Therapeutic siRNA for drug-resistant HER2-positive breast cancer.
about
Current development of targeted oligonucleotide-based cancer therapies: Perspective on HER2-positive breast cancer treatment.Silencing the roadblocks to effective triple-negative breast cancer treatments by siRNA nanoparticles.Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes.Lack of acquired resistance in HER2-positive breast cancer cells after long-term HER2 siRNA nanoparticle treatment.Lyophilization and stability of antibody-conjugated mesoporous silica nanoparticle with cationic polymer and PEG for siRNA deliveryMIS416 as a siRNA Delivery System with the Ability to Target Antigen-Presenting Cells
P2860
Therapeutic siRNA for drug-resistant HER2-positive breast cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 February 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Therapeutic siRNA for drug-resistant HER2-positive breast cancer.
@en
Therapeutic siRNA for drug-resistant HER2-positive breast cancer.
@nl
type
label
Therapeutic siRNA for drug-resistant HER2-positive breast cancer.
@en
Therapeutic siRNA for drug-resistant HER2-positive breast cancer.
@nl
prefLabel
Therapeutic siRNA for drug-resistant HER2-positive breast cancer.
@en
Therapeutic siRNA for drug-resistant HER2-positive breast cancer.
@nl
P2093
P2860
P356
P1433
P1476
Therapeutic siRNA for drug-resistant HER2-positive breast cancer
@en
P2093
David J Castro
Jingga Morry
Joe W Gray
Moataz M Reda
Wassana Yantasee
Worapol Ngamcherdtrakul
P2860
P304
14727-14741
P356
10.18632/ONCOTARGET.7409
P407
P50
P577
2016-03-01T00:00:00Z